Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:REGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeREGNRegeneron Pharmaceuticals$573.38+1.1%$562.59$476.49▼$1,170.58$60.12B0.35949,804 shs959,753 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceREGNRegeneron Pharmaceuticals+1.09%-1.26%+3.29%+16.25%-51.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeREGNRegeneron Pharmaceuticals$573.38+1.1%$562.59$476.49▼$1,170.58$60.12B0.35949,804 shs959,753 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceREGNRegeneron Pharmaceuticals+1.09%-1.26%+3.29%+16.25%-51.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceREGNRegeneron Pharmaceuticals 2.82Moderate Buy$817.6742.60% UpsideCurrent Analyst Ratings BreakdownLatest REGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025REGNRegeneron PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy8/27/2025REGNRegeneron PharmaceuticalsSanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$753.00 ➝ $781.008/27/2025REGNRegeneron PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$813.00 ➝ $831.008/14/2025REGNRegeneron PharmaceuticalsRedburn AtlanticSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/14/2025REGNRegeneron PharmaceuticalsRothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$890.008/11/2025REGNRegeneron PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$940.00 ➝ $812.008/4/2025REGNRegeneron PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$600.00 ➝ $640.008/4/2025REGNRegeneron PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$688.00 ➝ $695.008/1/2025REGNRegeneron PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$810.00 ➝ $815.008/1/2025REGNRegeneron PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$580.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookREGNRegeneron Pharmaceuticals$14.20B4.28$46.20 per share12.41$268.50 per share2.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateREGNRegeneron Pharmaceuticals$4.41B$39.6814.4515.081.9031.37%15.06%11.77%10/30/2025 (Estimated)Latest REGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/1/2025Q2 2025REGNRegeneron Pharmaceuticals$8.43$12.89+$4.46$12.81$3.30 billion$3.68 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthREGNRegeneron Pharmaceuticals$3.520.61%N/A8.87%N/ALatest REGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/1/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.6%8/18/20258/18/20259/3/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioREGNRegeneron Pharmaceuticals0.094.603.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipREGNRegeneron Pharmaceuticals83.31%Insider OwnershipCompanyInsider OwnershipREGNRegeneron Pharmaceuticals7.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableREGNRegeneron Pharmaceuticals15,106105.99 million98.55 millionOptionableREGN HeadlinesRecent News About These CompaniesRegeneron Pharmaceuticals, Inc. $REGN Position Reduced by Alliancebernstein L.P.3 hours ago | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Bought by AQR Capital Management LLC3 hours ago | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Raymond James Financial4 hours ago | marketbeat.comRegeneron Pharmaceuticals, Inc. (REGN): A Bull Case TheorySeptember 5 at 9:11 PM | finance.yahoo.comAmundi Purchases 52,166 Shares of Regeneron Pharmaceuticals, Inc. $REGNSeptember 5 at 6:24 AM | marketbeat.comAdage Capital Partners GP L.L.C. Has $58.82 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGNSeptember 5 at 6:08 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by Flputnam Investment Management Co.September 5 at 5:24 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by Royal Bank of CanadaSeptember 5 at 5:24 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Stock Position Lessened by Vident Advisory LLCSeptember 5 at 4:53 AM | marketbeat.comSanofi sheds $13 billion in value on weak trial results for eczema drugSeptember 4 at 10:08 PM | msn.comRegeneron Announces Updated Presentation Time for Upcoming Investor ConferenceSeptember 4 at 4:05 PM | globenewswire.comRegeneron Pharmaceuticals, Inc. (REGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeptember 4 at 4:03 PM | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN): A Bull Case TheorySeptember 4 at 1:50 PM | insidermonkey.comEvercore ISI Maintains a Buy on Regeneron Pharmaceuticals (REGN) With a $750 PTSeptember 3 at 10:51 PM | finance.yahoo.comRegeneron Pharmaceuticals, Inc. (REGN) Presents At Cantor Global Healthcare Conference 2025 (Transcript)September 3 at 5:01 PM | seekingalpha.comMichael Burry of Big Short Fame Loves These 3 StocksSeptember 3 at 8:54 AM | 247wallst.comRegeneron Pharmaceuticals, Inc. $REGN Shares Purchased by GW Henssler & Associates Ltd.September 3 at 7:52 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Baird Financial Group Inc.September 3 at 6:10 AM | marketbeat.comHow Is Regeneron’s Stock Performance Compared to Other Pharma Stocks?September 3 at 3:30 AM | barchart.comRegeneron: Drug Pricing Woes Notwithstanding, Due For A Major ComebackSeptember 2, 2025 | seekingalpha.comEvercore ISI Maintains a Buy on Regeneron Pharmaceuticals (REGN) With a $750 PTSeptember 2, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeREGN Company DescriptionsRegeneron Pharmaceuticals NASDAQ:REGN$573.38 +6.16 (+1.09%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$574.43 +1.05 (+0.18%) As of 09/5/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
